Exhibit 99.1
JPM Presentation 2024
Forward-Looking Statement and Disclaimer The presentation may contain
forward-looking statements. Statements made or presented may include statements that are not historical facts and are considered forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended. Words such as “believe,” “anticipate,” “plan,” “expect,” “intend,” “will,” “may,” “goal,” “potential,” “should,” “could,” “aim,” “estimate,” “predict,” “continue” and similar expressions or the
negative of these terms or other comparable terminology are intended to identify forward-looking statements, though not all forward-looking statements necessarily contain these identifying words. We intend these forward-looking statements to be
covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act and Section 21E of the Exchange Act. These forward-looking statements, including statements relating to the clinical,
therapeutic and market potential of our programs and product candidates, including the timing and success of our clinical development programs, including acoramidis for the treatment of transthyretin amyloidosis, low-dose infigratinib for the
treatment of achondroplasia, encaleret for the treatment of ADH1, BBP-418 for the treatment of LGMD2I, and other clinical programs; the progress of our ongoing and planned clinical trials; the availability of data from our clinical trials of
our product candidates; the potential benefits of our product candidates; the planned interactions with the FDA or other regulatory agencies, the timing and expectations of any potential regulatory submission and filing; the timing and success
of any potential commercial launch of our product candidates, reflect our current views about our plans, intentions, expectations and strategies, which are based on the information currently available to us and on assumptions we have made. Such
statements reflect the current views of the Company with respect to future events and are subject to known and unknown risks, including business, regulatory, economic and competitive risks, uncertainties, contingencies and assumptions about the
Company, including, without limitation, risks inherent in developing therapeutic products, and those risks and uncertainties described under the heading “Risk Factors” in the Company’s most recent Annual Report on Form 10-K filed with the U.S.
Securities and Exchange Commission (“SEC”) and in subsequent filings made by the Company with the SEC, which are available on the SEC’s website at www.sec.gov. In light of these risks and uncertainties, many of which are beyond the Company’s
control, the events or circumstances referred to in the forward-looking statements, express or implied, may not occur. The actual results may vary from the anticipated results and the variations may be material. You are cautioned not to place
undue reliance on these forward-looking statements, which speak to the Company’s current beliefs and expectations only as of the date of the presentation. Except as required by law, the Company disclaims any intention or responsibility for
updating or revising any forward-looking statements made or presented at the presentation in the event of new information, future developments or otherwise. No representation is made as to the safety or effectiveness of the product candidates
for the therapeutic use for which such product candidates are being studied. Certain information communicated at the presentation may relate to or is based on studies, publications, surveys and other data obtained from third-party sources and
the Company’s own internal estimates and research. While the Company believes these third-party sources to be reliable as of the date of the presentation, it has not independently verified, and makes no representation as to the adequacy,
fairness, accuracy or completeness of, any information obtained from third-party sources. In addition, certain information to be communicated at the presentation involves a number of assumptions and limitations, and there can be no guarantee as
to the accuracy or reliability of such assumptions. Finally, such research has not been verified by any independent source. Such information is provided as of the date of the presentation and is subject to change without notice. The Company
has not verified, and will not verify, any part of this presentation, and the Company makes no representation or warranty, express or implied, as to the accuracy or completeness of the information to be communicated at the presentation or as to
the existence, substance or materiality of any information omitted from the presentation at the presentation. The Company disclaims any and all liability for any loss or damage (whether foreseeable or not) suffered or incurred by any person or
entity as a result of anything contained or omitted from this document or the related presentation and such liability is expressly disclaimed.
We are at the starting line Focus for
today *https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7229282/#bib32 2024 Commercial development and execution Late-stage development Research & early development BridgeBio Business Segments ATTR-CM Achondroplasia, LGMD2i, ADH1, CAH –
all $1bn+ markets 10+ ongoing programs We are building a next generation integrated biotech that serves the 450+ million* genetic disease patients worldwide. To make BridgeBio durable, we will: Generate billions of peak year sales from
acoramidis Commercialize multiple best or first- in- class compounds Run a highly efficient and productive early-stage research engine
Where we play: genetic medicine, where it is still Day 1 8,000+ genetic diseases,
most without a therapy Higher probability of technical success versus other areas 100s of actionable opportunities to create first- or best-in-class drugs More information – UKB 500K whole genomes. The complete human reference genome More
insight on how to go from genetic signal to function Alpha Missense More established tools to target diseases at their source Massive opportunity to help Profound advances in science and medicine
How we play: our R&D engine is purpose-built for genetic medicine INDs under
$10m Time from start to IND < 3yrs Fast-to-fail decision criteria Incented teams on only their project Central resources to variabilize fixed cost Experience across 20+ trials,25+ countries, 500+ sites including key children’s
hospitals Deep regulatory & trial design expertise Efficient development Efficient discovery Decentralized for focus
We are at the starting line Focus for
today *https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7229282/#bib32 2024 Commercial development and execution Late-stage development Research & early development BridgeBio Business Segments ATTR-CM 10+ ongoing programs We are
building a next generation integrated biotech that serves the 450+ million* genetic disease patients worldwide. To make BridgeBio durable, we will: Generate billions of peak year sales from acoramidis Commercialize multiple best or first-
in- class compounds Run a highly efficient and productive early-stage research engine Achondroplasia, LGMD2i, ADH1, CAH – all $1bn+ markets
Learnings across ATTR-CM since JP Morgan 2023 Acoramidis provides unprecedented
absolute survival and hospitalization rates As a highly potent next generation stabilizer, acoramidis demonstrated absolute survival and hospitalization rates approaching age-matched general population1,2,3 Acoramidis demonstrated separation
at 3-months on ACM+CVH, the earliest known separation to date4 Stabilization levels achieved with acoramidis statistically correlate with downstream mortality at unprecedented levels5 Dramatic clinical improvements, independent of novel
therapies Clinical context has dramatically improved for ATTR-CM patients Placebo arm of ATTRibute-CM outperformed active tafamidis arm of ATTR-ACT6 ATTR-CM market is durable and growing Continued increase in diagnosis rates for ATTR-CM
The market is growing at approximately 15% Q on Q7 EU Opposition Division heard arguments regarding the validity of tafamidis claims in the polymorph patent and agreed with Pfizer, upholding the novelty and inventiveness claims, setting the
expectation that Vyndaqel will maintain market exclusivity through Aug. 2035 in EU8 Increased awareness around identifying progressors on existing treatment Significant remaining unmet need in ATTR-CM despite current on-market
therapies Ability to identify "non-responders“, those progressing on existing treatment, via NT-proBNP is ever improving 1ssa.gov. 2US Department of Health & Human Services 2018. 3Natural history reflects US Medicare non-neonatal,
non-maternal inpatient stays. ATTRibute-CM data reflect cardiovascular-related hospitalizations. 4ATTRibute-CM data, Kaplan-Meier of Composite ACM/CVH. 5Preliminary analyses (modeled data) from ATTRibute-CM. Comprehensive analysis to come in
2024. 6Masri et al., HFSA 2023 “A Multicenter Study Of Real-world Outcomes Of Tafamidis In Transthyretin Amyloid Cardiomyopathy”. Note: Direct cross-study comparisons may suggest misleading similarities or differences. 7Corporate SEC Filings.
8European Patent Office, Opposition Division, File #EP3191461
Near-complete TTR stabilization leads to improved clinical outcomes Early
separation in composite outcomes Unprecedented absolute survival and hospitalization rates A Evidence of improvement for large proportion of patients B C Patients on acoramidis are surviving more and going to the hospital less
Near-complete TTR stabilization leads to improved clinical outcomes Early
separation in composite outcomes Unprecedented absolute survival and hospitalization rates A Evidence of improvement for large proportion of patients B C Patients on acoramidis are surviving more and going to the hospital less
Near-complete TTR stabilization leads to improved clinical outcomes Early
separation in composite outcomes Unprecedented absolute survival and hospitalization rates A Evidence of improvement for large proportion of patients B C Patients on acoramidis are surviving more and going to the hospital less Amyloid
Regression1 TTR as Predictor of Survival1 1 Preliminary analyses from ATTRibute-CM. Comprehensive analysis to come in 2024.
Data from ATTRibute-CM demonstrate early increase in serum TTR is an independent
predictor of improved survival in ATTR-CM Statistical modeling demonstrates that acoramidis-mediated increase in serum TTR at Day 28 is an independent predictor of survival. A Source: Preliminary analyses (modeled data) from ATTRibute-CM.
Comprehensive analysis to come in 2024.
Higher serum TTR levels may be available to patients who switch from a partial
stabilizer to a potent, near-complete stabilizer Month 0 1 3 6 9 12 15 18 21 24 27 30 OLE: M1 M6 M12 Acoramidis Acoramidis+Tafamidis Placebo+Tafamidis Placebo Phase 3 OLE (Acoramidis only) Serum TTR Mean Change from
Baseline (mg/dL) (±SEM) Source: Data from ATTRibute-CM and OLE; The sample collection date is at least 14 days after tafamidis start date AND no more than 14 days after the tafamidis end date. OLE results are not shown for
Acoramidis+Tafamidis or Placebo groups due to ongoing analyses. In OLE, fraction of Acoramidis only patients continuing was n=222 of the n=234 at month 30, and fraction of Placebo+Tafamidis patients that qualify for OLE, given the above
collection dates, was n=21 of n=33 A
Preliminary evidence of amyloid regression on CMR imaging demonstrated in
ATTRibute-CM imaging sub-study ECV = Extracellular volume, an imaging correlate of amyloid deposition Source: Preliminary sample of ATTRibute-CM CMR imaging Regression ECV 65% ECV 58% ECV 68% ECV 78% Baseline Month 30 Increase in ECV
(red area) suggesting continued disease progression in placebo patient Decrease in ECV (red area) suggesting disease regression in acoramidis treated patient LV RV RA LA LV RV RA LA LV RV RA LA LV RV RA LA Acoramidis
Patient Placebo Patient Progression CMR ECV Imaging CMR ECV Imaging Note: Preliminary analyses / work in progress. Comprehensive analysis to come in 2024. B
We have hired a commercial team with strong CV experience and existing
relationships with COEs Undiagnosed patients and unmet need with currently approved medications fuels future market growth We are building a customer facing team that is sized to effectively maximize the opportunity Sources: Data on
file*COEs = Centers of Excellence Current tafamidis prescribers are made up mostly of cardiologists Prescriber Pool Evolution The TAF prescriber base has been growing at 30-50% annually 30-50% ~20% Tafamidis Prescriber Pool ATTR-CM
prescriber market is concentrated <100 US COEs* hold significant influence with prescribers & communicate overall product value State of Market Future State How we will win / how we will capitalize on this opportunity Precision
targeting along with a dedicated and experienced commercial team will lead to an optimal global launch
Backbone of Therapy Additional analyses from ATTRibute-CM Generate new evidence
to support diagnosis and treatment Continued Evidence Generation Access & Affordability Ensure broad and sustained access and affordability Design best-in-class patient and provider support Reinforce benefits of near-complete
stabilization Differentiate from partial stabilizers and partial knockdowns Commercial strategy and go-to-market plans in place to establish acoramidis as the backbone of ATTR-CM treatment upon launch in 2024 Dedicated
Focus Dedicated commercial and field-based team with singular focus on serving patients with ATTR-CM
Independent market research estimates 25-40% market share for acoramidis in a
future 4-product market Acoramidis Estimated Market Share as % of Future 4-Product Market 27-40% 25-30% 25-29% 25-40% Method 1 US Cardiologist Research N=184 Method 2 EU Cardiologist Research N=25 Method 3 US Cardiologist
Research N = 100 Range Acoramidis is poised to command significant market share regardless of potential positive knockdown data in 2024. Source: Market Research
Cardiovascular markets are dominated by orally administered products Source:
Evaluate Pharma Percentage of cardiovascular sales by route of administration
(%) 2013 2014 2015 2016 2017 2018 2019 2020 2021 90% 10% 90% 10% 89% 11% 88% 2012 87% 13% 87% 13% 87% 13% 87% 13% 87% 13% 87% 13% 2022 85% 15% 12% Oral Non-Oral With oral products dominating 85% of
cardiovascular sales in 2022, cardiologistsare best educated and equipped to administer oral therapeutics
Acoramidis go-to-market strategy in place ahead of anticipated 2024 launch with
robust lifecycle plans underway Detailed Results from ATTRibute-CM European Society of Cardiology August 2023 American Heart Association November 2023 Submit New Drug Application (NDA) with FDA November 2023 Submit additional regulatory
filings (EMA & others) 2024 Execute lifecycle management Initiate primary prevention study (ACT-EARLY) and QD Formulation 2024 Additional Clinical Data from ATTRibute-CM Future medical meetings Anticipated FDA Approval and
Commercial Launch 2H 2024
We are at the starting line Focus for
today *https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7229282/#bib32 2024 Commercial development and execution Late-stage development Research & early development BridgeBio Business Segments ATTR-CM 10+ ongoing programs We are
building a next generation integrated biotech that serves the 450+ million* genetic disease patients worldwide. To make BridgeBio durable, we will: Generate billions of peak year sales from acoramidis Commercialize multiple best or first-
in- class compounds Run a highly efficient and productive early-stage research engine Achondroplasia, LGMD2i, ADH1, CAH – all $1bn+ markets
Low-dose oral FGFR inhibitor (infigratinib) for achondroplasia Data from Cohort 5
of Phase 2 study of infigratinib presented this year 1PROPEL observational lead in study; 2Savarirayan 2020; 3FDA Summary Basis of Approval (imputed from individual waterfall charts) Genetic Driver FGFR3 gain-of-function Design
Principles Best-in-class (oral, potential greater efficacy, no hypotensive or injection-site reactions) Stage Phase 3 Total addressable market $5Bn Notes on status Achon Ph3 FPI achieved Robust enrollment (ahead of timelines) with LPI
expected in 1H241 and study completion in 2025 Hypochon. clinical program to initiate in 2024 Cohort 5 has demonstrated a well-tolerated safety profile, with: 0 severe adverse events 0 adverse events assessed as drug-related 0
discontinuations due to adverse events No accelerated advancement of bone age or worsening of body proportions 2 2 3
BBP-418 for Limb-Girdle Muscular Dystrophy Type 2I Genetic Driver FKRP partial
loss-of-function mutation Stage Phase 3 Total addressable market $1Bn+ Design principles First-in-class disease modifying treatment Key next steps Phase 3 is enrolling rapidly (ahead of projections) Completion of enrollment expected
1H24 for interim analysis in 1H25 Long-term data from ongoing Phase 2 study presented at major muscle meetings in 20231 The Phase 3 interim analysis endpoint is change from baseline in glycosylated αDG levels vs. placebo. Key secondary
endpoints include change from baseline in forced vital capacity (FVC) and 100-meter timed test (100mTT). 1World Muscle Society presentation, October 2023
Encaleret has the potential to restore physiologic mineral homeostasis in patients
with ADH1 Phase 2B results demonstrated rapid and sustained normalization of serum calcium, urine calcium, and serum PTH in response to encaleret therapy. No serious adverse events were reported with encaleret.2 Encaleret for autosomal
dominant hypocalcemia type 1 (ADH1) 1As specified by the primary endpoint of the CALIBRATE Phase 3 Study. 2Gafni R.I., NEJM, 2023, 389;13 (1245-47). Genetic Driver Gain-of-function variants in the calcium sensing receptor Stage Phase
3 Total addressable market $1Bn+ Design principles First-in-class disease-modifying treatment Key next steps Enrollment behind schedule owing to slow start-up at key academic investigational sites, but now progressing strongly Phase 3
readout expected early-2025 0% of participants on SoC at Screening in Phase 2B (N=13) 69% of participants on encaleret at Week 24 in Phase 2B (N=13)
Genetic Driver Loss of 21-hydroxylase Design Principle Best-in-class efficacy
(upstream and downstream effects) Stage Phase 2 Total addressable market $2Bn+ Loss of 21-hydroxylase in CAH causes loss of cortisol, and shunting of 17OHP into androgens BBP-631 for congenital adrenal hyperplasia (CAH) CRF1 antagonists
act here BBP-631 is designed to restore 21-hydroxylase
Early data show that BBP-631 is the first therapeutic option enabling classic CAH
patients to increase endogenous cortisol production; more follow-up is needed 1.7x 1.7x 5.4x 3.6x 67x 70x Fold increase in 11-deoxycortisol from baseline to Wk 12 In-clinic cortisol levels measured post-ACTH stim Pt. 1 Pt. 2 Pt.
3* Pt. 4 Pt. 5 Pt. 6** 1.5e13 vg/kg 3e13 vg/kg 6e13 vg/kg Pt. 5 Pt. 6 Baseline Pt. 5 Pt. 6 Wk 6 Pt. 5 Wk 12 Cortisol units: µg/dL 11-deoxycortisol units: ng/dL *Wk 12 not available; Wk 18 measurement used instead ** Pt. 6
only has 6 weeks of in-clinic measurement data available to date Transgene is active: We are seeing consistent,dose-dependent increases in 11-deoxycortisol… …Which is translating to early signs of cortisol production for both participants at
6e13 vg/kg Given the steep dose response seen to date and our bar for transformative data, we have commenced dosing Cohort 4 (1.2e14 vg/kg), with initial data available in Q3 2024
2024 at a high level Launch Acoramidis: Establish acoramidis as the backbone of
therapy in ATTR-CM Fully enroll our ongoing Phase 3 trials, and readout Phase 2 in CAH: Complete enrollment for achondroplasia, ADH1, LGMD2I, and make a go/no-go Phase 2 decision on our CAH program Establish a strong financial position:
$560mn of cash and equity investments1 with expected strategic optionality afforded by our diversified portfolio and large late-stage assets 1As of last earnings report 11/2/2023, BridgeBio Ended the third quarter with $522 million in cash,
cash equivalents, and short-term restricted cash, and $38 million of investments in equity securities